A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India
Status:
Not yet recruiting
Trial end date:
2024-06-10
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to learn about the safety and how well the study
medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic
Dermatitis (AD) in India. AD, also known as atopic eczema, is a chronic, relapsing skin
condition characterized by dry, itchy skin lesions which can affect any part of the body.
Adult peoples who participate in this study will take either 100 mg or 200 mg of abrocitinib
tablets by mouth for a duration of 12 weeks and adolescents will take for duration of 52
weeks. Knee Magnetic Resonance Imagine (MRI) will be done on adolescent peoples to determine
bone safety findings. We will examine the experiences of people receiving the study
medicines. This will help us determine if the study medicines are safe and how well they
work.